Stocktoria
ENDONOVO THERAPEUTICS, INC. ENDV
ENDONOVO THERAPEUTICS, INC. (ENDV) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2022 revenue was $135,355 at a -13649.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ENDV | ENDONOVO THERAPEUTICS, INC. | 3/9 | — | — | — |
| VANI | Vivani Medical, Inc. | 1/9 | -14.41 | — | — |
| NXL | Nexalin Technology, Inc. | 4/9 | — | — | — |
| POSC | POSITRON CORP | 2/9 | — | — | — |
| ITOC | iTonic Holdings Ltd | 1/9 | 5.57 | — | — |
| GTHP | GUIDED THERAPEUTICS INC | 3/9 | — | — | — |
| HCIL | Hongchang International Co., Ltd | 2/9 | 2.23 | — | — |
About ENDONOVO THERAPEUTICS, INC.
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardio chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular, and peripheral artery disease (PAD) and ischemic stroke. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.
FAQ
Is ENDV financially healthy?
ENDONOVO THERAPEUTICS, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does ENDV pay a dividend?
No, ENDONOVO THERAPEUTICS, INC. does not currently pay a dividend.
How profitable is ENDV?
In FY2022, ENDONOVO THERAPEUTICS, INC. had a net margin of -13649.2%.
Is ENDV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ENDONOVO THERAPEUTICS, INC.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2022-12-31. Facts plus Stocktoria's own computed scores — not investment advice.